PMID- 9225790
OWN - NLM
STAT- MEDLINE
DCOM- 19970807
LR  - 20161124
IS  - 0161-5505 (Print)
IS  - 0161-5505 (Linking)
VI  - 38
IP  - 7
DP  - 1997 Jul
TI  - Preclinical studies of indium-111-labeled IgM: a human monoclonal antibody for 
      infection imaging.
PG  - 1054-9
AB  - Indium-111-labeled plasma proteins, such as albumin, transferrin and IgG, have 
      been proven useful to image infection. We reported previously that 111In-labeled 
      human monoclonal antibody, IgM 16.88 (In-IgM) also would localize at the site of 
      infection. However, the kinetics of blood clearance, distribution and infection 
      uptake have not been investigated. We compared the kinetics of distribution and 
      infection uptake of In-IgM 16.88 with that of in-polyclonal IgG in rats with 
      focal infection. METHODS: Both IgM 16.88 and polyclonal IgG were labeled with 
      111In using a bifunctional chelating agent, LiLo. The labeling efficiency was > 
      95%. Focal infection was induced in rats by an intramuscular injection of E. Coli 
      in the right thigh. In-IgM (30-40 microCi) was injected into five groups of rats 
      (five rats/group). The rats were killed at 4, 8, 16, 24 and 36 hr. The percent 
      injected dose (%ID) in blood, infection muscle, control muscle, liver, spleen and 
      kidney were determined. Similar studies were performed with In-IgG. RESULTS: The 
      In-IgM activity in blood at 4 hr postinjection was 27% which decreased to 2% by 
      36 hr. In contrast, the In-IgG blood activity was 40% at 4 hr and 20% at 36 hr. 
      The infection/ muscle (I/M) ratios are higher with In-IgM at all time points 
      postinjection compared to that of In-IgG. At 24 hr, the I/M ratio was 22 compared 
      to 9 with In-IgG. At the same time point, the infection/ blood (I/B) ratio with 
      In-IgM was 2.7 compared to only 0.8 with that of In-IgG. In-IgM was taken up 
      mostly by the liver compared to diffuse abdominal uptake of IgG. CONCLUSION: 
      These result indicate that In-IgM produces higher lesion to background ratio when 
      compared to In-IgG and, therefore, is potentially useful to image infection in 
      patients.
FAU - Subramanian, R
AU  - Subramanian R
AD  - PerImmune, Inc., Rockville, Maryland 20850, USA.
FAU - Vallabhajoshula, S
AU  - Vallabhajoshula S
FAU - Lipszyc, H
AU  - Lipszyc H
FAU - Zhao, Q
AU  - Zhao Q
FAU - Murray, J
AU  - Murray J
FAU - Shaban, S
AU  - Shaban S
FAU - Machac, J
AU  - Machac J
FAU - Hanna, M G Jr
AU  - Hanna MG Jr
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Nucl Med
JT  - Journal of nuclear medicine : official publication, Society of Nuclear Medicine
JID - 0217410
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Chelating Agents)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulin M)
RN  - 0 (Indium Radioisotopes)
RN  - 134439-56-8 
      (1,3-bis(N-(N-(2-aminoethyl)-2-aminoethyl)-2-aminoacetamido)-2-(4-isothiocyanatobenzyl)propane-N,N,N',N'',N''',N'''',N''''',N'''''-octaaceticacid)
RN  - 7A314HQM0I (Pentetic Acid)
SB  - IM
MH  - Animals
MH  - *Antibodies, Monoclonal/pharmacokinetics
MH  - Chelating Agents
MH  - Female
MH  - Fluorescent Antibody Technique
MH  - Focal Infection/*diagnostic imaging/metabolism
MH  - Granulocytes/metabolism
MH  - Humans
MH  - Immunoglobulin G/immunology
MH  - Immunoglobulin M/*immunology
MH  - *Indium Radioisotopes/pharmacokinetics
MH  - Lymphocytes/metabolism
MH  - Male
MH  - Pentetic Acid/analogs & derivatives
MH  - *Radioimmunodetection
MH  - Rats
MH  - Tissue Distribution
EDAT- 1997/07/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1997/07/01 00:00
PHST- 1997/07/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1997/07/01 00:00 [entrez]
PST - ppublish
SO  - J Nucl Med. 1997 Jul;38(7):1054-9.